TRACER

Molecular imaging is a powerful patient stratification tool for targeted anticancer therapy clinical trials. So, how does it work? Anticancer agents only selectively bind to specific molecular markers on cancer cells. That is why you would only want to select patients with tumor characteristics that match your drug’s target. You can use molecular imaging to do this selection process for you. It provides whole-body information on target expression on an organ level. This is important because organs or tissues can have heterogeneous expressions of the target. With standard biopsies, you cannot show heterogeneous expression, but with molecular imaging you can. As a result, you end up with an individual blueprint per patient that tells you whether the patient’s tumor and possible metastases, can be treated by the targeted anticancer treatment. And if they are suitable for your first-in-human clinical trial. #molecularmonday #clinicaltrials #drugdevelopment #FDA #EMA

During the presentation TRACER recently gave at GOP, a Groninger enterprise award, the audience was so quiet you could hear a pin drop. When you first hear about imaging in drug development, it's mind-blowing. This may even apply to people who have worked in pharma for many years. Do you want to learn more about imaging for clinical trials? Or do you know someone who should know more about this? Let us know. Send a message or tag someone in the comments. #drugdevelopment #drugdiscovery #clinicaltrials #nuclearmedicine #contractresearch

#EANM24, it’s a wrap! Here’s Maarten Brom, Famke van Renesse - Brouwer and Tessa Aminetzah's takeaways after meeting with radiopharmaceutical developers and imaging clinical sites: - Acc-225 and Terbium supply chains are hot topics as demand rises - LU-177 has become more accessible for hospitals and developers since last year - Growing interest in novel targets aimed at treating inflammation and infection - Fast to clinic and reducing R&D time is a top priority for drug developers - The possibilities with whole body pet imaging are improving clinical trial design, making studies smarter and more precise - And finally, the question was raised if many should become nuclear oncologists… #hamburg #nuclearimaging #radiopharmaceuticals #inflammation

At TRACER, we've developed a new and unique approach to drug development, and we’re looking for someone with the expertise to take it to the next level. We’re hiring a Vice President of Operations (VPO) to lead our team and drive innovation in the clinical research space. If you have extensive experience in the drug development (contract research) industry and a passion for advancing new treatments, this is an exciting opportunity to make a real impact. Your leadership will be crucial as we apply our cutting-edge imaging methods to challenging clinical trials, pushing the boundaries of what’s possible in diagnostics and therapeutics. If you’re ready to bring your experience to a fast-growing, forward-thinking company, we’d love to hear from you. Learn more about this exciting opportunity on our website. Link in the comments. #Hiring #CRO #DrugDevelopment #Leadership #Innovation #Careers

At TRACER, we've developed a new and unique approach to drug development, and we’re looking for someone with the expertise to take it to the next level. We’re hiring a Vice President of Operations (VPO) to lead our team and drive innovation in the clinical research space. If you have extensive experience in the drug development (contract research) industry and a passion for advancing new treatments, this is an exciting opportunity to make a real impact. Your leadership will be crucial as we apply our cutting-edge imaging methods to challenging clinical trials, pushing the boundaries of what’s possible in diagnostics and therapeutics. If you’re ready to bring your experience to a fast-growing, forward-thinking company, we’d love to hear from you. Learn more about this exciting opportunity on our website. Link in the comments. #Hiring #CRO #DrugDevelopment #Leadership #Innovation #Careers

🧠 Breaking through the Blood-Brain Barrier with nanobodies for the treatment of neurological diseases 🧠 Delivering therapeutic compounds to the brain has long been a major challenge due to the highly selective Blood-Brain Barrier (BBB). Nanobodies are emerging as a potential solution. Nanobodies can cross the BBB by utilizing receptors that trigger Receptor-Mediated Transcytosis (RMT). This approach may literally "open doors" to targeted delivery of therapeutics for neurological diseases. Here are some innovative strategies researchers are exploring: 1️⃣ Nanobody FC5: Targets the α(2,3)-sialoglycoprotein receptor to shuttle other therapeutic proteins across the BBB. 2️⃣ Apolipoprotein E (ApoE): Binds to LRP1 receptors, enabling transcytosis to deliver therapeutic nanobodies into the brain. 3️⃣ Transferrin Receptor (TfR): This receptor, highly expressed in the brain, is another promising target to guide nanobodies into the brain. 4️⃣ Isoelectric Point Shifting: Adjusting the isoelectric point (pI) of nanobodies can further enhance their ability to cross the BBB. These developments could revolutionize treatments for conditions like #Alzheimer's, #Parkinson's, and brain tumors by providing targeted and efficient drug delivery to the brain. 🧬 How can TRACER help? We can label compounds and conduct imaging trials. This allows researchers to study the biodistribution and pharmacokinetics of a compound in preclinical but also in clinical studies. It can show, for instance, if the compound passes the BBB. #Nanobodies #Neurology #BloodBrainBarrier #Biotechnology #Therapeutics #MolecularMonday #DrugDelivery

Imagine, you lead a team of enthusiastic professionals with the ironclad will to change drug development. On a daily basis, you and this team are committed to bringing to reality the innovative method developed by TRACER. A method that you get to apply to challenging clinical trials. As our VPO, you will lead and oversee daily operations that help our team forward in their quest to innovate, and help TRACER to grow. You will bring expertise and support and therefore help develop medicines with the potential for enhanced diagnostics or even treatment. Are you getting excited? Then you just might become our new VPO. Check out the job posting on the TRACER website. Link in the comments below. #job #vacany #vacature #PharmaJobs #ClinicalJobs

We're excited that TRACER will be at the #EANM2024 in Hamburg from October 21-22. As part of the nuclear medicine and molecular imaging community, we look forward to connecting with colleagues and discussing the latest advancements in the field regarding clinical trials for radiopharmaceuticals. Also there? Feel free to reach out to Tessa Aminetzah, Famke van Renesse - Brouwer, or Maarten Brom – we’re looking forward to meeting you in person. https://lnkd.in/eiJmNHKT See you in Hamburg! #RadioPharma #NuclearMedicine #ClinicalResearch #Networking

How to track antibody delivery with preclinical fluorescent imaging? To track antibody delivery in preclinical models using fluorescent imaging, antibodies are tagged with a fluorescent dye. This allows researchers to use non-invasive imaging techniques to monitor how the antibodies distribute, where they accumulate, and how long they stay in the body. This provides researchers with an indication of their effectiveness. You, as a drug developer, can also add this option to your clinical research. Nuclear imaging can be used in addition to fluorescent imaging to overcome the limited penetration depth of fluorescence. By labeling your antibody with a nuclear isotope, antibody distribution can be made visible throughout the whole body. With precise antibody delivery tracking, drug developers can enhance their understanding of therapeutic distribution and efficacy. #molecularmonday #cancerresearch #preclinicalstudies #FluorescentImaging

To conclude Nuclear Medicine and Molecular Imaging Week, we at TRACER would like to thank everyone involved in the innovations shaping the future of imaging and its impact on patients’ lives. But the conversation doesn’t stop here! Every Monday, our #MolecularMonday posts dive deeper into cutting-edge topics from this science field - designed to keep you informed and inspired by the latest developments in imaging and molecular medicine. And of course, let’s connect next week at the #EANM2024, reach out to Tessa Aminetzah or Maarten Brom. Or simply contact us to schedule a meeting. #NuclearMedicineAndMolecularImagingWeek #NucMedImagingWeek #NMMIW #NuclearMedicineWeek #ImagingInnovation #DrugDevelopment #ScienceAndTechnology